Proteins of cardiomyopathic relevance were similarly mapped, and determined to include cardiac troponin I3 (TNI3), actin gamma 1 (ACTG1), actin alpha cardiac muscle 1 (ACTC1), tropomyosin (TPM), myosin light chain (MYL2-3), and myosin heavy chain (MYH6/7)
The oral version is currently in Phase II while Viking plans to kick off a Phase III trial for the injectable later this year
Lancet (2010) 375(9724):144756
The nutrition risk appears when a person on a GLP-1 medication was previously getting meaningful calories from alcohol and stops drinking without replacing any of that energy with food, deepening an already tight calorie envelope during a phase where protein targets are already hard to hit
How an endocrinologist actually decides In clinic, the decision between an oral GLP-1 pill and an injectable GLP-1 is built around the patient, not the medication